{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:10:12Z","timestamp":1785906612431,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/bmt.2015.328","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T14:53:26Z","timestamp":1452524006000},"page":"581-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience"],"prefix":"10.1038","volume":"51","author":[{"given":"J","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"key":"BFbmt2015328_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/MEG.0b013e328347322b","volume":"23","author":"Z Luo","year":"2011","unstructured":"Luo Z, Xie Y, Deng M, Zhou X, Ruan B . Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol 2011; 23: 695\u2013700.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFbmt2015328_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/jmv.23278","volume":"84","author":"ZL Fang","year":"2012","unstructured":"Fang ZL, Harrison TJ, Yang JY, Chen QY, Wang XY, Mo JJ . Prevalence of hepatitis B virus infection in a highly endemic area of southern China after catch-up immunization. J Med Virol 2012; 84: 878\u2013884.","journal-title":"J Med Virol"},{"key":"BFbmt2015328_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s15010-009-9019-1","volume":"38","author":"D Francisci","year":"2010","unstructured":"Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38: 58\u201361.","journal-title":"Infection"},{"key":"BFbmt2015328_CR4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11033-011-0851-x","volume":"39","author":"M Mirzaee","year":"2012","unstructured":"Mirzaee M, Yaghobi R, Ramzi M, Roshan Nia M . The prevalence of molecular and immunologic infective markers of hepatitis viruses in patients with hematological malignancies. Mol Biol Rep 2012; 39: 1217\u20131223.","journal-title":"Mol Biol Rep"},{"key":"BFbmt2015328_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(10)70167-4","volume":"11","author":"EA Engels","year":"2010","unstructured":"Engels EA, Cho ER, Jee SH . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010; 11: 827\u2013834.","journal-title":"Lancet Oncol"},{"key":"BFbmt2015328_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.22476","volume":"48","author":"MJ Tong","year":"2008","unstructured":"Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM . Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070\u20131078.","journal-title":"Hepatology"},{"key":"BFbmt2015328_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1097\/00029330-200712020-00002","volume":"120","author":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2007","unstructured":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120: 2159\u20132173.","journal-title":"Chin Med J (Engl)"},{"key":"BFbmt2015328_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1055\/s-2007-963714","volume":"45","author":"M Cornberg","year":"2007","unstructured":"Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007; 45: 1281\u20131328.","journal-title":"Z Gastroenterol"},{"key":"BFbmt2015328_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbmt.2005.09.001","volume":"12","author":"LT Hsiao","year":"2006","unstructured":"Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 84\u201394.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015328_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1399-3062.2012.00762.x","volume":"15","author":"BW Teh","year":"2013","unstructured":"Teh BW, Slavin MA, Szer J, Sasadeusz JJ . Hepatitis B serological changes following allogeneic bone marrow transplantation. Transpl Infect Dis 2013; 15: 98\u2013103.","journal-title":"Transpl Infect Dis"},{"key":"BFbmt2015328_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-5-46","volume":"5","author":"L Xuan","year":"2012","unstructured":"Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 2012; 5: 46.","journal-title":"J Hematol Oncol"},{"key":"BFbmt2015328_CR12","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/hep.26718","volume":"59","author":"C Hsu","year":"2014","unstructured":"Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59: 2092\u20132100.","journal-title":"Hepatology"},{"key":"BFbmt2015328_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209\u2013220.","journal-title":"Hepatology"},{"key":"BFbmt2015328_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/bjc.2011.4","volume":"104","author":"J Yun","year":"2011","unstructured":"Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 2011; 104: 559\u2013563.","journal-title":"Br J Cancer"},{"key":"BFbmt2015328_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al. Entecavir vs lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011\u20131020.","journal-title":"N Engl J Med"},{"key":"BFbmt2015328_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714\u20131722.","journal-title":"Gastroenterology"},{"key":"BFbmt2015328_CR17","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1128\/AAC.00833-06","volume":"51","author":"DJ Tenney","year":"2007","unstructured":"Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902\u2013911.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFbmt2015328_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3851\/IMP2277","volume":"17","author":"J Heo","year":"2012","unstructured":"Heo J, Park JY, Lee HJ, Tak WY, Um SH, Kim do Y et al. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther 2012; 17: 1563\u20131570.","journal-title":"Antivir Ther"},{"key":"BFbmt2015328_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001\u20131010.","journal-title":"N Engl J Med"},{"key":"BFbmt2015328_CR20","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","volume":"99","author":"GK Lau","year":"2002","unstructured":"Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324\u20132330.","journal-title":"Blood"},{"key":"BFbmt2015328_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/jhep.2002.35068","volume":"36","author":"GK Lau","year":"2002","unstructured":"Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702\u2013709.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"BFbmt2015328_CR22","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/S0168-8278(03)00318-0","volume":"39","author":"S Locarnini","year":"2003","unstructured":"Locarnini S . Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39 (Suppl 1): S124\u2013S132.","journal-title":"J Hepatol"},{"key":"BFbmt2015328_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","volume":"17","author":"RG Gish","year":"2010","unstructured":"Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17: 16\u201322.","journal-title":"J Viral Hepat"},{"key":"BFbmt2015328_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/blood-2005-02-0698","volume":"106","author":"CK Hui","year":"2005","unstructured":"Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005; 106: 464\u2013469.","journal-title":"Blood"},{"key":"BFbmt2015328_CR25","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1086\/314497","volume":"178","author":"GK Lau","year":"1998","unstructured":"Lau GK, Liang R, Lee CK, Yuen ST, Hou J, Lim WL et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis 1998; 178: 1585\u20131591.","journal-title":"J Infect Dis"},{"key":"BFbmt2015328_CR26","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","volume":"113","author":"R Liang","year":"2009","unstructured":"Liang R . How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147\u20133153.","journal-title":"Blood"},{"key":"BFbmt2015328_CR27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4049\/jimmunol.165.2.956","volume":"165","author":"A Ohta","year":"2000","unstructured":"Ohta A, Sekimoto M, Sato M, Koda T, Nishimura S, Iwakura Y et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. J Immunol 2000; 165: 956\u2013961.","journal-title":"J Immunol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015328","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:08:54Z","timestamp":1648062534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFbmt2015328"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.328","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]},"assertion":[{"value":"7 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}